Three sectors where Israeli technology companies have built globally significant businesses. We follow the publicly-listed ones — the companies with real, verifiable numbers.
🔐 Cybersecurity
Israel's cybersecurity sector is disproportionate in scale relative to the country's size. Unit 8200 alumni have founded more cybersecurity unicorns than any comparable talent pool globally, and the public companies — Check Point, CyberArk, and a wave of more recent IPOs — collectively represent tens of billions in market value.
Our coverage in this area goes beyond the "Israel is a cyber powerhouse" narrative that most outlets recycle. We look at what individual companies actually sell, how their revenue breaks down between product and services, what their gross margins reveal about competitive moats, and how their R&D spending trajectory compares to revenue growth. A cybersecurity company growing revenue at 25% while spending 40% more on R&D each year is telling a different story than one growing at 18% with flat R&D — and the 10-K filings make this visible if you know where to look.
We also track the competitive dynamics in specific sub-segments. Cloud security, endpoint protection, identity management, API security — each has a different set of Israeli players, and the overlap between them creates interesting comparative analysis opportunities. The rise of Wiz, which went from founding to a multi-billion valuation faster than almost any enterprise software company in history, has reshaped how we think about the Israeli cyber landscape. Our analysis focuses on what public data tells us about these shifts, referencing industry reports from Gartner and primary SEC filings.
We currently track approximately 40 publicly-listed Israeli companies with cybersecurity as their primary business, plus another 15 where cyber is a significant but not dominant revenue line.
Israel's agritech story starts with necessity — growing food in a desert — and has evolved into a global export industry. Drip irrigation, invented by Netafim in the 1960s, remains the foundational example, but today's Israeli agritech spans precision agriculture platforms, drone-based crop monitoring, AI pest detection, and biological crop protection.
The business side of agritech is uniquely challenging to analyze. These companies sell into a global agriculture market that is fragmented, seasonal, weather-dependent, and dominated by a handful of giant buyers (Bayer, Corteva, Syngenta). A precision farming startup might have amazing technology, but if its go-to-market strategy depends on convincing Midwestern corn farmers to switch platforms mid-season, the revenue ramp is going to be slow regardless of how good the product is. We spend time on these unit economics questions because they're what actually determine whether a company succeeds.
Our coverage examines both the technology and the business model: subscription vs. hardware sale, direct-to-farmer vs. through-agribusiness, recurring revenue retention rates, and the all-important question of whether customers expand their usage over time. For publicly-listed agritech firms, we also track geographic revenue concentration — a company with 60% of revenue from Brazil is exposed to different risks than one diversified across North America, Europe, and India. Data sources include company filings, FAO agricultural statistics, and industry analysis from firms covering the AgTech sector.
We currently track about 25 publicly-listed Israeli companies in the agritech space, ranging from established irrigation equipment manufacturers to early-stage precision agriculture platforms that recently went public.
Israel's medical device sector has a track record that few countries can match on a per-capita basis. Given Imaging created the ingestible PillCam and was acquired by Covidien for $860 million. Mazor Robotics pioneered surgical guidance systems and was bought by Medtronic for $1.6 billion. These exits created both wealth and expertise that seeded the next generation of Israeli medtech startups.
Medtech analysis requires a different framework than software. You can't just look at revenue growth — you have to understand FDA regulatory pathways (510(k) vs. PMA vs. De Novo), Medicare and private insurer reimbursement timelines, clinical trial phases and endpoints, and manufacturing scale-up economics. A device that works brilliantly in clinical trials at Sheba Medical Center might face a completely different reality when it needs to be manufactured at scale, sold into 200 different hospital procurement systems, and get reimbursed by CMS. We try to make this complexity readable.
Our coverage focuses on companies that have reached the public markets or are approaching that stage — the point where FDA filings, clinical trial registrations on ClinicalTrials.gov, and SEC disclosures provide enough data for meaningful analysis. We track approval timelines, reimbursement milestones, and the financial metrics that determine whether a medical device company is building toward sustainable profitability or burning cash on a product that the market won't adopt at scale. For context, we also reference FDA databases and Medicare coverage determination records.
We currently track approximately 35 publicly-listed Israeli medical device companies, covering cardiology, neurology, orthopedics, and diagnostic imaging.
⚡ Coverage boundary: OceanView covers publicly-listed Israeli technology companies for informational purposes. We do not rate, recommend, or predict the performance of any stock. Our analysis is based on public documents that anyone can access. Any investment decision is yours alone.
